{"id":11029,"date":"2023-11-08T10:05:18","date_gmt":"2023-11-08T10:05:18","guid":{"rendered":"https:\/\/infundpros.com\/markets\/biogen-reports-earnings-wednesday-heres-what-to-expect\/"},"modified":"2023-11-08T10:05:19","modified_gmt":"2023-11-08T10:05:19","slug":"biogen-reports-earnings-wednesday-heres-what-to-expect","status":"publish","type":"post","link":"https:\/\/infundpros.com\/?p=11029","title":{"rendered":"Biogen Reports Earnings Wednesday. Here’s What to Expect."},"content":{"rendered":"
\n
<\/p>\n

<\/p>\n

<\/p>\n<\/figure><\/div>\n

When
\n Biogen
\n reports earnings Wednesday, investors won\u2019t be paying much attention to the numbers.<\/p>\n

\n Biogen
\n (ticker: BIIB), under new CEO Chris Viehbacher, is in a period of cost-cutting, and trying to build out a new Alzheimer\u2019s disease franchise. There\u2019s not much mystery around the trajectory of its older products, sales of which are flat or dropping.<\/p>\n

\n

As for its Alzheimer\u2019s disease drug Leqembi, Biogen\u2019s partner
\n Eisai
\n (ESAIY), which is leading commercialization of the drug, said Tuesday that U.S. sales were \u00a50.4 billion ($2.7 billion) for the quarter.<\/p>\n

That number was lower than some had anticipated, but analysts wrote that sales growth was expected to be slow for Leqembi. Eisai\u2019s American depositary receipt dropped 4.8% on the results at midday Tuesday. <\/p>\n

\u201cToday\u2019s numbers shouldn\u2019t come as a surprise,\u201d Jefferies analyst Michael Yee wrote Tuesday of the Eisai results. \u201cEisai is making steady progress on the launch with more prescribers and hospital networks on board, but it will take time for sales to grow.\u201d<\/p>\n

Also on Tuesday, Biogen partner
\n Sage Therapeutics
\n (SAGE) said it will price the postpartum depression drug Zurzuvae\u2014which the companies are commercializing together\u2014at $15,900 for a two-week treatment course. Leerink Partners analyst Marc Goodman wrote that the price is lower than expected, and shares of Sage were down 4.9% at midday.<\/p>\n

As for Biogen, analysts will be listening Wednesday morning for any details on the Leqembi launch, updates on cost cuts, and the thinking on business development, according to UBS analyst Colin Bristow in a Nov. 1 note. Bristow wrote that the results and earnings call are unlikely to provide any \u201cneedle-moving\u201d updates.<\/p>\n

Analysts expect Biogen to report sales of $2.4 billion for the third quarter of its fiscal year, and earnings of $3.97 per share. In the same period last year, earnings were $4.77 per share.<\/p>\n

Biogen stock has fallen about 11% this year, and down more than 35% since early June 2021\u2014when shares spiked on excitement over Food and Drug Administration approval of the Alzheimer\u2019s drug Aduhelm, which has since proved to be essentially a commercial failure.<\/p>\n

In late October, Eisai said a new version of Leqembi that is injected under the skin cleared 14% more of the amyloid brain plaques thought to be associated with Alzheimer\u2019s disease than the currently approved medicine, which is administered via intravenous infusion. Rates of the condition known as ARIA\u2014a potentially dangerous brain swelling\u2014were slightly higher in patients who received the subcutaneous version, but Eisai said that the sample size was too small for exact comparisons to be made.<\/p>\n

Eisai expects to file for approval of the subcutaneous version of Leqembi by March of 2024.<\/p>\n

Biogen in July announced a cost-cutting program that it said would reduce its head count by 1,000 people, and save $700 million in net operating expenses.<\/p>\n

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com<\/p>\n<\/p><\/div>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

When Biogen reports earnings Wednesday, investors won\u2019t be paying much attention to the numbers. Biogen (ticker: BIIB), under new CEO Chris Viehbacher,…<\/p>\n","protected":false},"author":1,"featured_media":11030,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":{"0":"post-11029","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets"},"yoast_head":"\nBiogen Reports Earnings Wednesday. Here's What to Expect. | inFundPros<\/title>\n<meta name=\"description\" content=\"When Biogen reports earnings Wednesday, investors won\u2019t be paying much attention to the numbers. Biogen (ticker: BIIB), under new CEO Chris Viehbacher, is\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infundpros.com\/?p=11029\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen Reports Earnings Wednesday. Here's What to Expect. | inFundPros\" \/>\n<meta property=\"og:description\" content=\"When Biogen reports earnings Wednesday, investors won\u2019t be paying much attention to the numbers. Biogen (ticker: BIIB), under new CEO Chris Viehbacher, is\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infundpros.com\/?p=11029\" \/>\n<meta property=\"og:site_name\" content=\"inFundPros\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-08T10:05:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-08T10:05:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/11\/1699437918_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Press Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Press Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/infundpros.com\/?p=11029#article\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/?p=11029\"},\"author\":{\"name\":\"Press Room\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\"},\"headline\":\"Biogen Reports Earnings Wednesday. Here’s What to Expect.\",\"datePublished\":\"2023-11-08T10:05:18+00:00\",\"dateModified\":\"2023-11-08T10:05:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/infundpros.com\/?p=11029\"},\"wordCount\":483,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"articleSection\":[\"Markets\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/infundpros.com\/?p=11029#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/infundpros.com\/?p=11029\",\"url\":\"https:\/\/infundpros.com\/?p=11029\",\"name\":\"Biogen Reports Earnings Wednesday. Here's What to Expect. | inFundPros\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/#website\"},\"datePublished\":\"2023-11-08T10:05:18+00:00\",\"dateModified\":\"2023-11-08T10:05:19+00:00\",\"description\":\"When Biogen reports earnings Wednesday, investors won\u2019t be paying much attention to the numbers. Biogen (ticker: BIIB), under new CEO Chris Viehbacher, is\",\"breadcrumb\":{\"@id\":\"https:\/\/infundpros.com\/?p=11029#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/infundpros.com\/?p=11029\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/infundpros.com\/?p=11029#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/infundpros.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen Reports Earnings Wednesday. Here’s What to Expect.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/infundpros.com\/#website\",\"url\":\"https:\/\/infundpros.com\/\",\"name\":\"Fintech Advance\",\"description\":\"Latest Finance and Tech News and Updates\",\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/infundpros.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/infundpros.com\/#organization\",\"name\":\"Fintech Advance\",\"url\":\"https:\/\/infundpros.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"width\":409,\"height\":70,\"caption\":\"Fintech Advance\"},\"image\":{\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\",\"name\":\"Press Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"caption\":\"Press Room\"},\"sameAs\":[\"https:\/\/infundpros.com\"],\"url\":\"https:\/\/infundpros.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biogen Reports Earnings Wednesday. Here's What to Expect. | inFundPros","description":"When Biogen reports earnings Wednesday, investors won\u2019t be paying much attention to the numbers. Biogen (ticker: BIIB), under new CEO Chris Viehbacher, is","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infundpros.com\/?p=11029","og_locale":"en_US","og_type":"article","og_title":"Biogen Reports Earnings Wednesday. Here's What to Expect. | inFundPros","og_description":"When Biogen reports earnings Wednesday, investors won\u2019t be paying much attention to the numbers. Biogen (ticker: BIIB), under new CEO Chris Viehbacher, is","og_url":"https:\/\/infundpros.com\/?p=11029","og_site_name":"inFundPros","article_published_time":"2023-11-08T10:05:18+00:00","article_modified_time":"2023-11-08T10:05:19+00:00","og_image":[{"width":1280,"height":640,"url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/11\/1699437918_social.jpeg","type":"image\/jpeg"}],"author":"Press Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Press Room","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infundpros.com\/?p=11029#article","isPartOf":{"@id":"https:\/\/infundpros.com\/?p=11029"},"author":{"name":"Press Room","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff"},"headline":"Biogen Reports Earnings Wednesday. Here’s What to Expect.","datePublished":"2023-11-08T10:05:18+00:00","dateModified":"2023-11-08T10:05:19+00:00","mainEntityOfPage":{"@id":"https:\/\/infundpros.com\/?p=11029"},"wordCount":483,"commentCount":0,"publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"articleSection":["Markets"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/infundpros.com\/?p=11029#respond"]}]},{"@type":"WebPage","@id":"https:\/\/infundpros.com\/?p=11029","url":"https:\/\/infundpros.com\/?p=11029","name":"Biogen Reports Earnings Wednesday. Here's What to Expect. | inFundPros","isPartOf":{"@id":"https:\/\/infundpros.com\/#website"},"datePublished":"2023-11-08T10:05:18+00:00","dateModified":"2023-11-08T10:05:19+00:00","description":"When Biogen reports earnings Wednesday, investors won\u2019t be paying much attention to the numbers. Biogen (ticker: BIIB), under new CEO Chris Viehbacher, is","breadcrumb":{"@id":"https:\/\/infundpros.com\/?p=11029#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infundpros.com\/?p=11029"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/infundpros.com\/?p=11029#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infundpros.com\/"},{"@type":"ListItem","position":2,"name":"Biogen Reports Earnings Wednesday. Here’s What to Expect."}]},{"@type":"WebSite","@id":"https:\/\/infundpros.com\/#website","url":"https:\/\/infundpros.com\/","name":"Fintech Advance","description":"Latest Finance and Tech News and Updates","publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infundpros.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/infundpros.com\/#organization","name":"Fintech Advance","url":"https:\/\/infundpros.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","width":409,"height":70,"caption":"Fintech Advance"},"image":{"@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff","name":"Press Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/person\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","caption":"Press Room"},"sameAs":["https:\/\/infundpros.com"],"url":"https:\/\/infundpros.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/11029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11029"}],"version-history":[{"count":1,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/11029\/revisions"}],"predecessor-version":[{"id":11031,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/11029\/revisions\/11031"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/media\/11030"}],"wp:attachment":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}